(FDA) approved the combination of Cyra... - Lung Cancer Support

Lung Cancer Support

4,067 members2,215 posts

(FDA) approved the combination of Cyramza (ramucirumab) and Tarceva (erlotinib) for the first line treatment of advanced NSCLC

Miranda_GO2 profile image
Miranda_GO2Partner
0 Replies

On May 29th, 2020, the Food and Drug Administration (FDA) approved the combination of Cyramza (ramucirumab) and Tarceva (erlotinib) for the first line treatment of advanced non-small cell lung cancer (NSCLC) with tumors having changes in EGFR called exon 19 deletions or exon 21 L858R mutations. The FDA based their approval on the results of the clinical trial RELAY which showed that patients receiving Cyramza and Tarceva went longer periods of time without progression and their response to treatment lasted longer than those receiving Tarceva by itself.

The combination Cyramza and Tarceva and being available as a first line targeted therapy option gives patients whose tumors have changes in EGFR a new choice for treatment.

To read the FDA press release, here is the link: fda.gov/drugs/drug-approval...

If you have any questions about this approval or others, please reach out to support@go2foundation.org

Written by
Miranda_GO2 profile image
Miranda_GO2
Partner
To view profiles and participate in discussions please or .
Read more about...

Not what you're looking for?

You may also like...

FDA Approves Tecentriq for First-Line Treatment of Metastatic NSCLC with High PD-L1 Expression

On May 18th, 2020, the Food and Drug Administration (FDA) approved Tecentriq (atezolizumab) for the...
Miranda_GO2 profile image
Partner

Opdivo and Yervoy combination approved for Non-small cell lung cancer

More exciting approval announcements for this week. On May 15th, 2020, the Food and Drug...
Miranda_GO2 profile image
Partner

First Targeted Adjuvant Therapy for EGFR Non Small Cell Lung Cancer (stage IB-IIIA)

On December 18th, 2020, the Food and Drug Administration (FDA) approved Tagrisso (osimertinib) for...
Miranda_GO2 profile image
Partner

An immunotherapy now approved for first-line treatment

Late yesterday, the FDA approved Keytruda (an immunotherapy) as a first-line treatment for patients...

Call it stable or call it NED...whatever, I’ll take it!

Every day should be a good day but today was a really good day. PET/CT and brain MRI showed zero...
PegD profile image

Moderation team

See all
AmyKamp profile image
AmyKampAdministrator
SarahMcHale profile image
SarahMcHaleAdministrator
Maureen-GO2 profile image
Maureen-GO2Administrator

Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.

Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.